Neuropsychiatric Manifestations of Cardiovascular Drug Therapy

Heart Disease

Volumn 1, Issue 4, 1999, Pages 241-254

  Keller, Seth ^a,c   Frishman, William H ^a   Epstein, Jonathan ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b YESHIVA UNIVERSITY   (United States)

^c BETH ISRAEL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI ARRHYTHMIA AGENTS; ANTIARRHYTHMIC AGENT; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; CARDIOVASCULAR AGENT; VASODILATOR AGENT;

DRUG EFFECT; HUMAN; NERVOUS SYSTEM; REVIEW;

ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; CARDIOVASCULAR AGENTS; HUMAN; NERVOUS SYSTEM; VASODILATOR AGENTS;

EID: 0033188464     PISSN: 1521737X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (227)

1. Paykel ES, Fleminger R, Watson JP. Psychiatric side effects of antihypertensive drugs other than reserpine. J Clin Psychopharmacol 1982;2:14-39.
2. Pottash ALC, Black HR, Gold MR. Psychiatric complications of antihypertensive medications. J Nerv Mental Dis 1981;169:430-438.
3. Haynes RB, Sackett DL, Taylor DW, Gibson ES, Johnson AL. Increased absenteeism from work after detection and labeling of hypertensive patients. N Engl J Med 1978;299:741-744 .
4. Raft D, Spencer RF, Tooney T, Brogan D. Depression in medical outpatients: use of the Zung scale. Dis Nervous Sys 38:1977;38:999-1004.
5. Dollery CT, Emslie-Smith D, Milne MD. Guanethidine in the treatment of hypertension. Lancet 1960;3:381-387.
6. Secdat YK, Pillay VKG. Further experience with guanethidine: a clinical assessment of 103 patients. Smith Afr Med J 1966;1:140-142.
7. Stocks AE, Robertson A. The long-term therapy of severe hypertension with guanethidine. Am Heart J 1967;73:569-570.
8. Evanson JM, Seers HTN. Comparison of bretylium tosylate with guanethidine in the treatment of severe hypertension. Lancet 1960;3:387-389.
9. Goodwin KK, Ebart MH, Bunney WE. Mental effects of reserpine in man: a review. In, Shader RI (ed.): Complications of Medical Drugs. New York: Raven Press, 1972;73-101.
10. Rauch SK, Stern TA, Zusman RM. Neuropsychiatric considerations in the treatment of hypertension. Int J Psychiatry Med 1991;21:291-308.
11. Fries ED. Mental depression in hypertensive patients treated for long periods with large doses of reserpine. N Engl J Med 1954;251:1006.
12. Quetsch RM, Achor RWP, Litin EM, Faucett RL. Depressive reaction in hypertensive patients: a comparison of those treated with rauwolfia and those receiving no specific antihypertensive treatment. Circulation 1959;19:366-375.
13. Schroeder HA, Perry HM. Psychosis apparently produced by reserpine. JAMA 1955;159:839-840.
14. Kass I, Brown EC. Treatment of hypertensive patients with rauwolfia compounds and reserpine. JAMA 1955;159:1513-1516.
15. Ayd FJ. Drug induced depression: fact or fallacy. N Y J Med 1958;58:354-356.
16. Wurzelmann J, Frishman WH, Aronson M, Masur D, Ooi WL. Neuropsychological effects of antihypertensive drugs. Cardiol Clin 1987;5:689-701.
17. Barsa JA, Kline NS. Treatment of 200 disturbed psychotics with reserpine. JAMA 1955;158:110-113.
18. Maggs R, Ellison RM. Five year follow up of reserpine therapy in mental hospital practice. J Mental Sci 1960;106:590-598.
19. Tooney G, Isberg EM, Gottlieb JS. The use of reserpine in an acute psychiatric setting. Arch Neurol Psych 1959;81:325.
20. Flach FF. Clinical effectiveness of reserpine. Ann N Y Acad Sci 1955;61:161.
21. Gahgon LH. Ineffectiveness of chlorpromazine and rauwolfia serpentina preparations in the treatment of depression. Dis Nerv Sys 1957;18:390-393.
22. Kinross-Wright V. Chlorpromazine and reserpine in the treatment of psychoses. Ann N Y Acad Sci 1955;61:174-182.
23. Adler S. Methyldopa induced decrease in mental activity. JAMA 1974;230: 1428-1429.
24. Backeland F, Lundwall L. Effects of methyldopa on sleep patterns in man. Electroencephalogy Clin Neurophysiol 1971;31:269-273.
25. Thornton WE. Dementia induced by methyldopa with haloperidol. N Engl J Med 1976;294:1222.
26. Fullerton AG, Morton-Jenkins D. Methyldopa and depression. Br Med J 1963; 1:538-539.
27. Dubach VC. Methyldopa and depression. Br Med J 1963;1:261.
28. Strange RR. Parkinsonism occurring during methyldopa therapy. Can Med Assoc J 1966;95:928-929.
29. Markhorn CH, Clark WG, Winters WD. Effects of alpha-methyldopa and reserpine in Huntington's chorea, Parkinson's disease and other movement disorders. Life Sci 1963;9:697-705.
30. Paykel ES. Hallucinosis in combined methyldopa and pargyline. Br Med J 1966;1:803.
31. Schwarz D, Michel D, Strian F. Depressive reaktioner unter antihypertensive behandlung. Arch Psychiatr Nerverkr 1973;218:41-50.
32. Gossop M. Clonidine and the treatment of the opiate withdrawal syndrome. Drug Alcohol Defend 1988;21:253-259.
33. Gold MS, Redmond DE, Kleber HD. Clonidine blocks acute opiate withdrawal symptoms. Lancet 1978;2:599-602.
34. Johnson JM. Psychiatric uses of antiadrenergic and adrenergic blocking drugs. J Nerv Ment Dis 1984;172:123-132.
35. Wilkins AJ, Jenkins WJ, Steiner JA. Efficacy of clonidine in treatment of alcohol withdrawal states. Psychopharmacology 1983;81:78-80.
36. Baumgartner GR, Rowen RC. Clonidine versus chlordiazepoxide in the management of acute alcohol withdrawal syndrome. Arch Intern Med 1987;147: 1223-1226.
37. Cushman P. Clonidine and alcohol withdrawal. Adv Alcohol Subst Abuse 1988; 7:17-28.
38. Robinson BJ, Robinson GM, Maling TJB, Johnson RH. Is clonidine useful in the treatment of alcohol withdrawal? Alcohol Clin Exp Res 1989;13:95-98.
39. Ozdemir V, Brenner KE, Naranjo CA. Treatment of alcohol withdrawal syndrome. Ann Intern Med 1994;26:101-105.
40. Gourlay SG, Benowitz NL. Is clonidine an effective smoking cessation therapy? Drugs 1995;50:197-207.
41. 40a. Cohen DJ, Young JG, Nathanson JA, Shaywitz BA. Clonidine in Tourette's syndrome. Lancet 1979;2:551-553.
42. Cohen DJ, Riddle MA, Leckman JF. Pharmacotherapy of Tourettes syndrome and associated disorders. Psychiatr Clin North Am 1992;15:109-129.
43. O'Carroll RE, Moffoot A, Embier KP, Murray C, Goodwin GM. Korsakoff's syndrome, cognition and clonidine. Psychol Med 1993;23:341-347.
44. McEntee WJ, Mair RG. Memory enhancement in Korsakoff's psychosis by clonidine: further evidence for a noradrenergic deficit. Ann Neurol 1980;7: 466-470.
45. Seno S, Shaw SM, Christian JE. Distribution and urinary excretion of furosemide in the rat. J Pharmacol Sci 1969;58:935-938.
46. Lewis WH. Iatrogenic psychotic depressive reaction in hypertensive patients. Am J Psychiatry 1971;127:1416-1417.
47. Okada F. Depression after treatment with thiazide diuretics for hypertension. Am J Psychiatry 1985;142:1101-1102.
48. Moss HB, Procci WR. Sexual dysfunction associated with oral antihypertensive medication: a critical survey of the literature. Gen Hosp Psychiatry 1982;4:121-129.
49. Williams GH, Croog SH, Levine S, Testa MA, Sudilovsky A. Impact of antihypertensive therapy on quality of life: effect of hydrochlorothiazide. J Hypertens 1987;5(Suppl):S29-S35.
50. Trummer E. Sex problems in practice: iatrogenic sex problems. Br Med J Clin Res 1981;283:953-955.
51. Alarcon-Segovia D, Wakim KG, Worthington JW, Ward LE. Clinical and experimental studies on the hydralazine syndrome and its relationship to systemic lupus erythematosis. Medicine 1967;46:1-35.
52. Benson D, Peterson LG, Bartay J. Neuropsychiatric manifestations of antihypertensive medications. Psychol Med 1983;1:205-214.
53. Chin DKF, Cho AK, Tse CY. Neuropsychiatric complications related to use of prazosin in patients with renal failure. Br Med J 1986;293:1347.
54. Dimsdale JF, Newton RP, Joist T. Neuropsychological side effects of beta blockers. Arch Intern Med 1989;149:514-525.
55. Keller S, Frishman WH, Nurenberg JR. Neuropsychiatric effects of cardiovascular medications. In, Frishman WH, Sonnenblick EH (eds.): Cardiovascular Pharmacotherpeutics. New York: McGraw Hill, 1997;1053-1071.
56. Viadero JJ, Wong SH, White WB. Acute psychotic behavior associated with atenolol. Am J Psychiatry 1983;140:1382.
57. Arber N. Delirium induced by atenolol. Br Med J 1988;297:1048.
58. Kramer BA. Severe confusion in a patient receiving electroconvulsive therapy and atenolol. J Nerv Ment Dis 1986;174:562-563.
59. Applegate WB, Pressel S, Wittes J, Luhr J, Shekelle RB, Camel GH, et al. Impact of the treatment of isolated systolic hypertension on behavioral variables: results from the Systolic Hypertension in the Elderly program. Arch Intern Med 1994;154:2154-2160.
60. Gerstman BB, Jolson HM, Bauer M, Cho P, Livingston JM, Platt R. The incidence of depression in new users of beta-blockers and selective antihypertensives. J Clin Epidemiol 1996;49:809-815.
61. Frishman WH, Razin A, Swenciones C, Sonnenblick EH, Update: beta adrenoceptor blockade in anxiety states: a new approach to therapy? Cardiovasc Rev Rep 1992;13:8-31.
62. Kathol RG, Noyes R, Slymen DJ, Crowe RR, Claney J, Kerber RE. Propranolol in chronic anxiety disorders. Arch Gen Psychiatry 1980;37:1361-1365.
63. Lader M. Beta adrenoceptor antagonists in neuropsychiatry: an update. J Clin Psychiatry 1988;48:213-223.
64. Tyrer P. Current status of beta blocking drugs in the treatment of anxiety disorders. Drugs 1988;36:773-783.
65. Noyes R Jr. Beta adrenergic blocking drugs in anxiety and stress. Psychiatr Clin North Am 1985;8:119-132.
66. Brantigan CO, Brantigan TA, Joseph N. Effect of beta-blockade and betastimulation on stage fright. Am J Med 1982;72:88-94. Psychopharmacol 1982;9:22-27.
67. Brantigan CO, Brantigan TA, Joseph N. Effect of beta-blockade and betastimulation on stage fright. Am J Med 1982;72:88-94. Psychopharmacol 1982;9:22-27.
68. Consider beta-blockers when somatic symptoms of anxiety predominate. Drug Ther Perspect 1996;8:9.
69. Liebowitz MR, Gorman JM, Fyer AJ, Campeas R, Levin AP, Sandberg D, et al. Pharmacotherapy of social phobia: an interim report of a placebo controlled comparison of phenelzine and atenolol. J Clin Psychiatry 1988;49:252-257.
70. Lydiard RB, Brawman-Mitzner O, Ballenger JC. Recent developments in the psycho-pharmacology of anxiety disorders. J Consult Clin Psychol 1996;64: 660-668.
71. Liebowitz MR, Schncier F, Campeas R, Hollander E, Hatterer J, Fyer A, et al. Phenelzine vs. atenolol in social phobia. Arch Gen Psychiatry 1992;49:290-300.
72. Hoehn-Saric R, McLoed DR. Cardiac symptoms and anxiety disorders: contributing factors and pharmacologic treatment. Am J Cardiol 1987;60:68J-73J.
73. Krantz DS, Contrada RJ, LaRiccia PJ, Anderson JR, Durel LA, Dembroski TM, Weiss T. Effects of beta adrenergic stimulation and blockade on cardiovascular reactivity, affect and type A behavior. Psychosom Med 1987;49:146-158.
74. Prakash R, Campbell TW, Petrie WM. Psychoses with propranolol: a case report. Can J Psychiatry 1983;28:657-658.
75. Berlant JL. One more look at propranolol for the treatment of refractory schizophrenia. Schizophr Bull 1987;13:705-714.
76. Hanssen T, Heyden T, Sundberg T, Weetenberg L, Alfredson G, Nyback H. Propranolol in schizophrenia: clinical metabolic and pharmacologic findings. Arch Gen Psychiatry 1988;37:685-690.
77. Peet M, Middlemiss DN, Yates RA. Propranolol in schizophrenia. II. Clinical and biochemical aspects of combining propranolol with chlorpromazine. Br J Psychiatry 1981;138:112-117.
78. Perenyi A, Farkas A. Propranolol in the treatment of Tardive dyskinesia. Biol Psychiatry 1983;18:391-394.
79. Adler L, Angrist B, Pesclow E, Corwin J, Maslansky R, Rotrosen J. A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. Br J Psychiatry 1986;149:42-45.
80. Ratey JJ, Sergi P, Polakoff S. Nadolol as a treatment of akathisia. Am J Psychiatry 1985;142:640-642.
81. Elliott FA. Propranolol for the control of belligerant behavior following acute brain damage. Ann Neurol 1977;1:489-491.
82. Brooke MM, Patterson DR, Questad KA, Cardenas D, Parrel-Roberts L. The treatment of agitation during initial hospitalization after traumatic brain injury. Arch Phys Med Rehabil 1992;73:917-921.
83. Rosenbaum A, Hoge S. Head injury and marital aggression. Am J Psychiatry 1989;146:1048-1051. 1981;138:218-220.
84. Rosenbaum A, Hoge S. Head injury and marital aggression. Am J Psychiatry 1989;146:1048-1051. 1981;138:218-220.
85. Greendyke RM, Kanter DR. Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double blind study. J Clin Psychiatry 1986;47:423-426.
86. Greendyke RM, Berkner JP, Webster JC, Gulya A. Treatment of behavioral problems with pindolol. Psychosomatics 1989;30:161-165.
87. Ratey JJ, Mikkelsen EJ, Smith GB, Upadhyaya A, Zuckerman HS, Martell D, et al. Beta blockers in the severely and profoundly mentally retarded. J Clin Psychopharmacol 1986;6:103-107.
88. Weiler PJ, Mungas D, Bernick C. Propranolol for the control of disruptive behavior in senile dementia. J Geriatr Psychiatry Neurol 1988;1:226-230.
89. Shankle W, Nielson K, Cotman C. Low-dose propranolol reduces aggresion and agitation resembling that associated with orbitofrontal dysfunction in elderly demented patients. Alzheimer Dis Assoc Disord 1995;9:233-237.
90. Fava M. Psychopharmacologic treatment of pathologic aggression. Psychiatr Clin North Am 1997;20:427-451.
91. Mattes JA. Psychopharmacology of temper outbursts: a review. J Nerv Ment Dis 1986;174:464-470.
92. Jacob MS, Zilm DH, MacLeod SM, Sellers EM. Propranolol-associated confused states during alcohol withdrawal. J Clin Psychopharmacol 1983;3:185-187
93. Kraus ML, Gottlieb LD, Horwitz RI, Anscher M. Randomized clinical trial of atenolol in patients with alcohol withdrawal. N Engl J Med 1985;31:905-909.
94. Mayo-Smith MF. Pharmacological management of alcohol withdrawal: a meta-analysis and evidence-based practice guideline. JAMA 1997;278:144-151.
95. Abernethy DR, Greenblatt DJ, Shader RI. Treatment of diazepam withdrawal syndrome with propranolol. Ann Intern Med 1981;94:354-355.
96. Tyrer P, Rutherford D, Huggett T. Benzodiazepine withdrawal symptoms and propranolol. Lancet 1981;1:520-522.
97. Nurenberg JR. Intravenous nitroglycerine in the management of post-treatment hypertension during electroconvulsive therapy. J Nerv Ment Dis 1991; 179:291-294.
98. Hoschl G. Do calcium antagonists have a place in the treatment of mood disorders? Drugs 1991;42:721-729.
99. Dassylva B. Verapamil may cause depression. Can J Psychiatry 1993;38:299-300.
100. Lyndon RW, Johnson G, McKeough G. Nifedipine induced depression. Br J Psychiatry 1991;36:447-448.
101. Jacobsen FM, Sack DA, James SP. Delirium induced by verapamil. Am J Psychiatry 1987;144:248.
102. Fogelman J. Verapamil caused depression, confusion and impotence. Am J Psychiatry 1988;145:380.
103. Ahmad S. Nifedipine-induced acute psychosis. J Am Geriatr Soc 1994;32:408.
104. Binder EF, Cayabyab L, Ritchie DJ, Birge SJ. Diltiazem-induced psychosis and a possible diltiazem-lithium interaction. Arch Intern Med 1991;151:373-374.
105. Busche CJ. Organic psychosis caused by diltiazem. J R Soc Med 1988;81:296-297.
106. Palat GK, Movahed A. Secondary mania associated with diltiazem. Clin Cardiol 1986;9:39.
107. Dubovsky SL. Calcium antagonists in manic-depressive illness. Neuropsychobiology 1993;27:184-192.
108. Hollister LE, Garza-Trevino ES. Calcium channel blockers in psychiatry. Prog Drug Res 1996;47:279-292.
109. Balon R, Ramesh C. Calcium channel blockers for anxiety disorders? Ann Clin Psychiatry 1996;8:215-220.
110. Dubovsky SL, Buzan RD. Novel alternatives and supplements to lithium and anticonvulsants for bipolar affective disorder. J Clin Psychiatry 1997;58:224-242.
111. Dubovsky SL, Franks RD, Lifschitz M, Coen P. Effectiveness of verapamil in the treatment of a manic patient. Am J Psychiatry 1982;139:502-504.
112. Gitlin MJ, Weiss J. Verapamil as maintenance treatment in bipolar illness: a case report. J Clin Psychopharmacol 1984;4:341-343.
113. Kennedy S, Ozersky S, Robillard M. Refractory bipolar illness may not respond to verapamil. J Clin Psychopharmacol 1986;6:316-317.
114. Dubovsky SL, Franks RD, Schrier D. Phenelzine-induced hypomania: effect of verapamil. Biol Psychiatry 1985;20:1009-1014.
115. Pollack MH, Rosenbaum JF. Verapamil in the treatment of recurrent unipolar depression. Biol Psychiatry 1987;22:779-782.
116. Jacques RM, Cox SJ. Verapamil in major (psychotic) depression. Br J Psychiatry 1991;158:124-125.
117. Johnson BA, Gowen PJ. Calcium channel blockade and resistant bipolar depression. Irish J Psychol Med 1991;8:50-51.
118. Dose M, Emrich HM, Cording-Tommel C, Von Zerssen D. Use of calcium antagonists in mania. Psychoneuroendocrinology 1986;11:241-243.
119. Giannini AJ, Loiselle RH, Price WA, Giannini MC. Comparison of antimanic efficacy of clonidine and verapamil. J Clin Pharmacol 1985;25:307-308.
120. Dubovsky SL, Franks RD, Allen S, Murphy J. Calcium antagonists in mania: a double blind study of verapamil. Psychiatry Res 1986;18:309-320.
121. Hoschl C, Kozemy J. Verapamil in affective disorders: a controlled double blind study. Biol Psychiatry 1989;25:128-140.
122. Garza Tevino ES, Overall JE, Hollister LE. Verapamil versus lithium in acute mania. Am J Psychiatry 1992;149:121-122.
123. Walton SA, Berk M, Brokk S. Superiority of lithium over verapamil in mania: a randomized, controlled, single-blind trial. J Clin Psychiatry 1996;57:543-546.
124. Caillard V. Treatment of mania using a calcium antagonist: preliminary trial. Neuropsychobiology 1985;14:23-26.
125. Brunet G, Cerlich B, Robert P, Dumas S, Souetre E, Darcourt G. Open trial of a calcium antagonist, nimodipine, in acute mania. Clin Neuropsychopharmacol 1990;13:224-228.
126. Eccleston D, Cole AJ. Calcium-channel blockade and depressive illness. Br J Psychiatry 1990;156:889-891.
127. Lindelius R, Nilsson CG. Flunarazine as maintenance treatment of a patient with bipolar disorder. Am J Psychiatry 1992;149:139.
128. Barton BM, Gitlin MJ. Verapamil in treatment-resistant mania: an open trial. J Clin Psychopharmacol 1987;7:101-103.
129. Mogilnicka E, Czyzak A, Maj J. Dihydropyridine calcium channel antagonists reduce immobility in the mouse behavioral despair test: antidepressants facilitate nifedipine action. Eur J Pharmacol 1987;138:413-416.
130. Wells BG. Verapamil in the treatment of schizophrenia. Drug Intell Clin Pharm 1990;24:838-840.
131. Tourjman SV, Bloom DM, Nair NPV. Verapamil in the treatment of chronic schizophrenia. Psychopharmacol Bull 1987;23:227-229.
132. Schepelern S, Koster A. Verapamil in the treatment of severe schizophrenia. Acta Psychiatr Scand 1987;75:557-558.
133. Reiter S, Adler L, Angrist B, Peselow E, Rotrosen J. Effects of verapamil on Tardive dyskinesia and psychosis in schizophrenic patients. J Clin Psychiatry 1989;50:26-27.
134. Pickar D, Wolkowitz OM, Doran AR. Clinical and biochemical effects of verapamil administration to schizophrenic patients. Arch Gen Psychiatry 1987; 44:113-118.
135. Grebb JA, Shelton RG, Taylor EH, Bigelow LB. A negative, double blind, placebo controlled clinical trial of verapamil in chronic schizophrenia. Biol Psychiatry 1986;21:691-694.
136. Price WA, Pascarzi GA. Use of verapamil to treat negative symptoms in schizophrenia. J Clin Psychopharmacol 1987;7:357.
137. Price WA. Antipsychotic effects of verapamil in schizophrenia. J Clin Psychiatry 1987;9:225-230.
138. Goldstein JA. Calcium channel blockers in the treatment of panic disorders. J Clin Psychiatry 1985;46:546.
139. Klein E, Uhde TW. Controlled study of verapamil for the treatment of panic disorder. Am J Psychiatry 1988;145:431-434.
140. Goldstein JA. Nifedipine treatment of Tourettes Syndrome. J Clin Psychiatry 1984;45:360.
141. Walsh TL, Lavenstein B, Licamele WI, Bronheim S, O Leary J. Calcium antagonists in the treatment of Tourette s disorder. Am J Psychiatr 1986;143: 1467-1468.
142. Ban TA, Morey I, Aguglia E, Azzarelli O, Balosano F, Marigliano V, et al. Nimodipine in the treatment of old age dementia. Prog Neuropsychopharmacol Biol Psychiatry 1990;14:525-551.
143. Tollefson GD. Short-term effects of the calcium channel blocker nimodipine in the management of primary degenerative dementia. Biol Psychiatry 1991;27: 1133-1142.
144. Rodnitzky RL. Can calcium antagonists provide a neuroprotective effect in Parkinson's disease? Drugs 1999;57:845-849.
145. Zubenko GS, Nixon RA. Mood elevating effects of captopril in depressed patients. Am J Psychiatry 1984;141:110-111.
146. Croog SH, Levine S, Testa MA, Brown B, Bulpitt CJ, Jenkins CD, et al. The effects of hypertensive therapy on quality of life. N Engl J Med 1986;314: 1657-1664.
147. Dicken RF. Captopril treatment of depression. Biol Psychiatry 1986;21:1425-1428.
148. Germain L, Chouinard G. Treatment of unipolar recurrent major depression with captopril. Biol Psychiatry 1988;23:637-641.
149. Germain L, Chouinard G. Captopril treatment of major depression with serial measurements of blood cortisol concentrations. Biol Psychiatry 1989;25:489-493.
150. Vuckovic A, Cohen BM, Zubenko GS. The use of captopril in treatment-resistant depression: an open trial. J Clin Psychopharmacol 1991;11:395-396.
151. Patten SB, Brager N, Sanders S. Manic symptoms associated with the use of captopril. Can J Psychiatry 1991;36:314-315.
152. Gajula RP, Berlin RM. Captopril induced mania. Am J Psychiatry 1993;150: 1429-1430.
153. Skop BP, Masterson BJ. Mania secondary to lisinopril therapy. Psychosomatics 1995;36:508-509.
154. Patterson JF. Depression associated with enalapril. South Med J 1989;82:402-403.
155. Patten SB, Williams JVA, Love EJ. Case-control studies of cardiovascular medications as risk factors for clinically diagnosed depressive disorders in a hospitalized population. Can J Psychiatry 1996;41:469-476.
156. Gillman MA, Sandyk R. Reversal of captopril-induced psychosis with nalaxone. Am J Psychiatry 1985;142:270.
157. Haffner CA, Smith BS, Pepper C. Hallucinations as an adverse effect of angiotensin converting enzyme inhibition. Postgrad Med J 1993;69:240.
158. Riordan JF. Angiotensin converting enzyme inhibitors and alcohol abuse. EXS 1994;71:323-331.
159. Sudilovsky A, Cutler NR, Sramek JJ, Wardle T, Veroff AE, Mickelson W, et al. A pilot clinical trial of the angiotensin converting enzyme inhibitor ceranapril in Alzheimer disease. Alzheimer Du Assoc Disord 1993;7:105-111.
160. Goldstein JA. Captopril in the treatment of psychogenic polydypsia. J Clin Psychiatry 1986;47:99.
161. Carvajal A, Lerida MT, Sanchez A, Martin LH, deDiego IM. ACE inhibitors and impotence: a case series from the Spanish Drug Monitoring System. Drug Safety 1995;13:130-131.
162. Phillips MI. Functions of angiotensin in the central nervous system. Ann Rev Physiol 1987;49:413-435.
163. Ranidive SA, Chen AX, Serajjuden AT. Relative lipophilicities and structural-pharmacological considerations of various angiotensin converting enzyme inhibitors. Pharmacol Res 1992;9:1480-1486.
164. Cushman DW, Wang FL, Fung WC, Harvey CM, DeForrest JM. Differentiation of angiotensin converting enzyme (ACE) inhibitors by their selective inhibition of ACE in physiologically important target organs. Am J Hypertens 1989;2:294-306.
165. Amegui A, Penny EK, Rossor M, Tomlinson BE. Angiotensin converting enzyme in Alzheimers disease increased activity in caudate nucleus and cortical areas. J Neurochem 1982;38:1490-1492.
166. Koller M, Krause HP, Hoffmeister F, Ganten D. Endogenous brain angiotensin II disrupts passive avoidance behavior in rats. Neurosci Lett 1979;14:71-75.
167. Losartan. Med Lett Drugs Ther 1995;37:57-59.
168. Ahmad S. Losartan and reversible psychosis. Cardiology 1996;87:569-570.
169. Roden DM. Antiarrhythmic drugs. In, Harden JG, Limbrid LE, Gilman A, et al (eds.): Goodman and Gilman's The Pharmacological Basis of Therapeutics. Ninth edition. New York: McGraw Hill, 1996;839-874.
170. Schubert DSP, Gabinet L. Psychosis induced by sustained release procainamide. Can Med Assoc J 1984;131:1188-1190.
171. Rice H, Haltzman S, Tucek C. Mania associated with procainamide. Am J Psychiatry 1988;145:129-130.
172. Johnson AG, Day RO, Seldon WA. A functional psychosis precipitated by quinidine. Med J Aust 1990;153:47-49.
173. Deleu D, Schmedding E. Acute psychosis as idiosyncratic reaction to quinidine: report of two cases. Br Med J 1987;294:1001-1002.
174. Gilbert GJ. Quinidine dementia. Am J Cardiol 1978;41:791.
175. Billig N, Buongiorno P. Quinidine induced organic mental disorders. J Am Geriatr Soc 1985;33:504-506.
176. Ahmad S. Disopyramide-induced acute psychosis. Chest 1979;76:712.
177. Ahmad S. Disopyramide and impotence. South Med J 1980;73:958.
178. Lewis DO. Serendipitous relief with disopyramide of phobia for flying. Am J Psychiatry 1983;140:1387.
179. Pfeifer HJ, Greenblatt DJ, Koch-Weser J. Clinical use and toxicity of intravenous lidocaine: a report from the Boston Collaborative Drug Surveillance Program. Am Heart J 1976;92:168-173.
180. Wyman MG, Lalka D, Hammersmith L, Cannom DS, Goldreyer BN. Multiple bolus technique for lidocaine administration during the first hours after an acute myocardial infarction. Am J Cardiol 1978;41:313-317.
181. Sarvay SM, Marke J, Steinberg MD, Rabiner CJ. "Doom anxiety" and delirium in lidocaine toxicity. Am J Psychiatry 1987;144:159-163.
182. Lloyd B, Greenblatt D. Neuropsychiatric sequelae of pharmacotherapy of cardiac arrhythmias and hypertension. J Clin Psychopharmacol 1981;1:394-398.
183. Bikadoroff G. Mental changes associated with tocainide, a new antiarrhythmic. Can J Psychiatry 1987;32:219-221.
184. Clarke CWF, El-Mahdi EO. Confusion and paranoia associated with oral tocainide. Postgrad Med J 1985;61:79-81.
185. Ramhamadany E, Mackenzie S, Ramsdale DR. Dysartria and visual hallucinations due to flecainide toxicity. Postgrad Med J 1986;62:61-62.
186. Bennett MI. Paranoid psychosis due to flecainide toxicity in malignant neuropathic pain. Pain 1997;70:93-94.
187. Trohman RG, Castellanos D, Castellanos A, Kessler K. Amiodarone-induced delirium. Ann Intern Med 1988;108:68-69.
188. Ahmad S. Amiodarone and sexual dysfunction. Am Heart J 1995;130:1320-1321.
189. Sweadner KJ. Overview: subunit diversity in the Na-K ATPase. In, Kaplan JH, DeWeer R (eds.): The Sodium Pump: Structure, Mechanism and Regulation. New York: Rockefeller University Press, 1991;63-76.
190. Duroziez P. De delire et du coma digitaliques. Gaz Hebedo de Med et de Chir 1874;11:780-785.
191. Smith HL. Cerebral manifestations of digitalis intoxication. Mayo Clin Proc 1938;13:574-575.
192. King L. Digitalis delirium. 1950;33:1360-1372.
193. Smith H, Janz TG, Erker M. Digoxin toxicity presenting as altered mental status in a patient with severe chronic obstructive lung disease. Heart Lung 1992;21:78-80.
194. Eisendrath SJ, Sweeny MA. Toxic neuropsychiatric effects of digoxin at therapeutic serum concentrations. Am J Psychiatry 1987;144:506-507.
195. Greenblatt DJ, Shader RI. Digitalis toxicity. In, Shader RI (ed.): Psychiatric Complications of Medical Drugs. New York: Raven Press, 1972;25-47.
196. Patten SB, Love EJ. Neuropsychiatric adverse reactions: passive reports to Health and Welfare Canada's Adverse Drug Reaction Database (1965-present). Int J Psychiatry Med 1994;24:45-62.
197. Wardle J. Cholesterol and psychological well being. J Psychosom Res 1995;39: 549-562.
198. Muldoon MF, Manuck SB, Matthews KA. Lowering cholesterol concentrations and mortality: a quantitative review of primary prevention trials. Br Med J 1990;301:309-314.
199. Rossouw JE, Lewis H, Rifkind BM. The value of lowering cholesterol after myocardial infarction. N Engl J Med 1990;323:1112-1119.
200. Ravnskov U. Cholesterol lowering trials in coronary heart disease: frequency of citation and outcome. Br Med J 1992;305:15-19.
201. Davey Smith G, Song F, Sheldon TA. Cholesterol lowering and mortality: the importance of considering initial level of risk. Br Med J 1993;306:1367-1373.
202. Law MR, Thompson SG, Wald NJ. Assessing possible hazards of reducing serum cholesterol. Br Med J 1994;308:373-379.
203. Jacobs D, Blackburn H, Higgins M, Reed D, Iso H, McMillan G, Neaton J, et al. Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation 1992;86:1046-1060.
204. Frank JW, Reed DM, Grove JS, Benfante R. Will lowering population levels of serum cholesterol affect total mortality? J Clin Epidemiol 1992;45:333-346.
205. Neaton JD, Blackburn H, Jacobs D, Kuller L, Lee DJ, Sherwin R, et al. Serum cholesterol level and mortality findings for men screened in the Multiple Risk Factor Intervention Trial. Arch Intern Med 1992;152:1490-1500.
206. Pekkanen J, Nissien A, Punsar S, Karvonen MJ. Serum cholesterol and the risk of accidental or violent death in a 25 year follow up: the Finnish Cohorts of the Seven Countries Study. Arch Intern Med 1989;149:1589-1591.
207. Davey Smith G, Shipley MJ, Marmot MG, Rose G. Plasma cholesterol concentrations and mortality: the Whitehall Study. JAMA 1994;267:70-76.
208. Markovitz JH, Smith D. Raczynski JM, Oberman A, Williams OD, Knox S, Jacobs DR Jr. Lack of relations of hostility, negative affect, and high risk behavior with low plasma lipid levels in the Coronary Artery Risk Development in Young Adults study. Arch Intern Med 1997;157:1953-1959.
209. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study. Lancet 1994;344:1383-1389.
210. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, et al, for the West of Scotland Coronary Prevention Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995;333:1301-1307.
211. Lines C. Hazards of reducing cholesterol. Br Med J 1994;309:541.
212. Downs JR, Oster G, Santanello NC, for the Air Force Coronary Atherosclerosis Prevention Study Research Group. HMG-CoA reductase inhibitors and quality of life. JAMA 1993;269:3107-3108.
213. Wardie J, Armitage J, Collins R, Wallendzus K, Keech A, Lawson A. Randomised placebo controlled trial of effect on mood ot lowering cholesterol concentration. Br Med J 1996;313:75-78.
214. Duits N, Bos FM. Depressive symptoms and cholesterol lowering drugs. Lancet 1993;341:114.
215. Kassler-Taub B, Woodward T, Markowitz JS. Depressive symptoms and pravastatin. Lancet 1993;341:371-372.
216. Lechleitner M, Hoppichler F, Konwalinka G, Parsch JR, Braunstemer H, Depressive symptoms in hypercholesterolaemic patients treated with pravastatin. Lancet 1992;340:910.
217. Engelberg H. Low cholesterol and suicide. Lancet 1992;339:727.
218. Schaefer EJ. HMG CoA reductase inhibitors for hypercholesterolemia. N Engl J Med 1988;319:1222-1223.
219. Barth JD, Kruisbrink OAE, VanDijk AL. Inhibitors of hydroxy-methylglutaryl coenzyme A reductase for treating hypercholesterolemia. Br Med J 1990;301: 669.
220. Simvastatin. Lancet 1992;339:547.
221. Rosenson RS, Goranson NL. Lovastatin-associated sleep and mood disorders Am J Med 1993;95:548-549.
222. Vgontzas AN, Kales A, Bixler EO, Manfredi RL, Tyson KL. Effects of lovastatin and pravastatin on sleep efficiency and sleep stages. Clin Pharmacol Ther 1991;50:730-737.
223. Roth T, Richardson GR, Sullivan JP, Lee RM, Merlotti L, Rohers T. Comparative effects of pravastatin and lovastatin on nighttime sleep and daytime performance. Clin Cardiol 1992;15:426-432.
224. Botti RE, Triscari J, Pan HY, Zayat J. Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 1991;14:256-261.
225. Figueras A, Castel JM, LaPorte JR, Capella D. Gemfibrozil induced impotence. Ann Pharmacother 1993;27:982.
226. Bharani A. Sexual dysfunction after gemfibrozil. Br Med J 1992;305:693.
227. Schneider J, Kaffarnick H. Impotence in patients treated with clofibrate. Atherosclerosis 1975;21:455-457.